Current and Future Standards in Treatment of Myasthenia Gravis
Current and Future Standards in Treatment of Myasthenia Gravis
About this item
Full title
Author / Creator
Publisher
New York: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Myasthenia gravis (MG) is a prototypic antibody-mediated neurological autoimmune disorder. Herein we characterize modern treatment algorithms that are adapted to disease severity, and introduce the current principles of escalating strategies for MG treatment. In non-thymoma patients younger than about 50 years of age and with generalized weakness,...
Alternative Titles
Full title
Current and Future Standards in Treatment of Myasthenia Gravis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4514693
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4514693
Other Identifiers
ISSN
1933-7213,1878-7479
E-ISSN
1878-7479
DOI
10.1016/j.nurt.2008.08.011
